Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Efficacy & Safety
Factor VIII Threshold

Efficacy & safety

Patient demand and expectation has transformed over the decades


Different patients have different needs – and require treatment targeted at different FVIII threshold levels4

Patient Need Sedentary lifestyle Mild risk activity Moderate risk activity High risk activity
Treatment Threshold (%) 1 3 5 10+

Adapted from lorio et al. 20174

Until the mid-1970s, patients were often advised to avoid physical activity1

We now know that being able to participate in physical activity is important to patients and improves joint stability2,3

While patient-bleeding phenotype will be influential, it’s generally accepted that today’s prophylaxis goal is to keep rFVIII levels as HIGH as possible for as long as possible4,5,6


  • Goto M, Takedani H, Yokota K, Haga N, et al. Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Med. 2016:7;85–98. Return to content
  • Steen Carlsson K, Andersson E, Berntorp. Preference-based valuation of treatment attributes in haemophilia A using web survey. Haemophilia. 2017;23(6): 894-903. Return to content
  • Kargarfard M, Dehghadani M, Ghias R. The Effect of Aquatic Exercise Therapy on Muscle Strength and Joint’s Range of Motion in Hemophilia Patients. Int J Prev Med. 2013;4(1):50-6. Return to content
  • Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23(3):e170-e179. Return to content
  • Collins P. Personalized prophylaxis. Haemophilia. 2012;18 (Suppl. 4):131–135. Return to content
  • Shah A, Solms A, Garmann D. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A. Clin Pharmacokinet. 2017;56(9):1045-1055. Return to content